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Abstract
Background: The majority of individuals with fragile X syndrome (FXS) have in-
tellectual disability, behavioral problems, autism, and language deficits. IQ typically 
declines with age in boys with the full mutation. The results of preclinical studies 
demonstrated that metformin, a biguanide used to treat type 2 diabetes, rescues mul-
tiple phenotypes of FXS in both Drosophila and mouse models. Preliminary studies 
of patients with FXS demonstrated improvements in behavior.
Methods: Here, we present two cases of individuals who have been treated with 
metformin clinically for one year.
Results: Both patients demonstrated significant cognitive and behavioral improve-
ments. They also improved eating habits and normalization of their weight percentiles.
Conclusion: Metformin may be a candidate drug for treatment of several types of 
symptoms in individuals with FXS.
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1 |  INTRODUCTION
Metformin (N,N‐dimethylbiguanide), the antidiabetic agent 
with a favorable risk/benefit profile, is one of the most widely 
prescribed drugs in the world. Metformin is in clinical use for 
more than 60 years and its pharmacokinetic and pharmaco-
dynamic properties are well established. Metformin has been 
used in Europe for treatment of diabetes mellitus type 2 since 
1957 (Foretz, Guigas, Bertrand, Pollak, & Viollet, 2014).
There are studies documenting that metformin could be a 
helpful medication to decrease weight in insulin sensitive and 
insulin resistant overweight and obese adult patients (Seifarth, 
Schehler, & Schneider, 2013). In addition, Metformin is ef-
fective in the treatment of obesity with and without diabe-
tes mellitus type 2, in a cohort of children (Jones, Arslanian, 
Peterokova, Park, & Tomlinson, 2002; Klein, Cottingham, 
Sorter, Barton, & Morrison, 2006; Park, Kinra, Ward, White, 
& Viner, 2009). It can be used for the treatment of polycystic 
ovary disease, diabetic nephropathy, gestational diabetes and 
cardiovascular complications associated with diabetes melli-
tus type 2 (Foretz et al., 2014; Viollet et al., 2012). This med-
ication has benefits associated with decreased cancer risk and 
improved cancer prognosis (Romero et al., 2017; Viollet et 
al., 2012).
There is a clear difference between the mechanism of ac-
tion during acute and chronic use of metformin. Preclinical 
studies indicated that the mechanism involves AMP‐activated 
protein kinase (AMPK)‐dependent, as well as AMPK‐inde-
pendent pathways, inhibition of mitochondrial respiration 
and activity of the mitochondrial enzyme glycerophosphate 
dehydrogenase (Rena, Hardie, & Pearson, 2017).
The symptoms in patients with fragile X syndrome (FXS; 
phenotype MIM number: 300624) are related to the absence 
or deficiency of FMRP, a protein which plays a key role in 
protein translation which is important for neuronal synaptic 
connections. There is an upregulation of the metabotropic 
glutamate 5 (mGluR5) pathway, the insulin receptor and the 
mTOR pathway in the absence of FMRP (Gantois, Popic, 
Khoutorsky, & Sonenberg, 2019; Hagerman et al., 2017). 
This dysregulation leads to global developmental delays in 
males and continued IQ decline in childhood and adolescence 
(Wright‐Talamante et al., 1996). Individuals with FXS typi-
cally manifest social and behavioral problems such as atten-
tion‐deficit/hyperactivity disorder (ADHD), anxiety, autism 
spectrum disorder (ASD) and aggression (Rajaratnam et al., 
2017) Many children and adults with FXS have eating prob-
lems, including overstuffing their mouth, overeating and lack 
of satiation after meals causing obesity in 31% (McLennan, 
Polussa, Tassone, & Hagerman, 2011).
The use of metformin in the animal models, such as 
Drosophila FXS and FXS knock out (KO) mouse demon-
strated that metformin could improve FXS phenotypes, the 
circadian rhythm deficits and memory deficits (Gantois et 
al., 2017; Monyak et al., 2017). Pathogenically overactive 
signaling pathways in FXS in the central nervous system 
could also be normalized by metformin (Gantois et al., 
2017,2019).
Recently, we published data which documented 
that metformin was helpful in seven individuals aged 
4–60  years with FXS, characterized by a full mutation 
(>200  CGG repeats) of FMR1 (gene/locus MIM num-
ber: 309550; the GenBank reference sequence and version 
number: NC_000023.11) (Dy et al., 2018). These patients 
demonstrated improvements in their eating habits, weight 
loss, and behavior as measured by the Aberrant Behavior 
Checklist. In addition, the families reported that the pa-
tient's language level improved and in several cases these 
patients were able to carry out conversations.
In this report, we present two adult individuals with FXS 
who have been treated with metformin for 1 year and demon-
strated improvements in their IQ scores and behavior.
2 |  MATERIALS AND METHODS
2.1 | Ethical Compliance
Both patients signed an informed consent for developmental 
and molecular testing approved by the institutional IRB and 
all families have consented to have their case histories and 
clinical response to metformin published.
The cases described in this article are seen frequently for 
management of FXS at the Fragile X Treatment and Research 
Center at the University of California Davis MIND Institute. 
We described each patient with their medical histories, phys-
ical features, behavioral symptoms focusing on qualitative 
reports from the individuals’ primary care providers, and IQ 
scores as well as their laboratory findings pre‐ and posttreat-
ment. Both of the cases were prescribed metformin to treat 
their FXS. According to the results of our previous study, the 
medication was prescribed as part of their clinical care and 
was targeting irritability, social responsiveness, hyperactiv-
ity, social avoidance, as well as language and conversational 
skills (Dy et al., 2018; Gantois et al., 2019). The regular 
metformin adult dose is 1,000 mg twice a day. If no diar-
rhea occurs, Metformin can be titrated up to this dose. They 
were both observed for intellectual, behavioral and metabolic 
changes.
The level of cognitive functioning was determined through 
the administration of the Stanford–Binet Intelligence Scale, 
Fifth Edition (SB‐5), a cognitive functioning test that has ro-
bust psychometric properties, minimal practice effects, and 
correlates highly with other measures of intelligence. This 
was performed before the introduction of metformin and after 
1 year of usage of metformin. The Stanford Binet assessment 
was done by the same examiner for both participants at all 
time points. The behaviour observations correspond to his 
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age between 22 to 25 years. During this time period he was 
continuously treated with metformin.
All information for both individuals was obtained by par-
ents’ reports, as well as review of Clinic visit notes and re-
view of previous reports.
3 |  RESULTS
3.1 | Case 1
This case is a 25‐year‐old male diagnosed with FXS, autism 
and ADHD with a history of hyperphagia and lack of satiety 
after meals.
He met the criteria for autism (ADOS, Module 3 score 
of 18, above the cut‐off score for ASDs) and his Full‐Scale 
IQ was 57 with a verbal IQ of 64 and a nonverbal IQ of 
57 on the Stanford‐Binet scale when he was 13. He was 
diagnosed with FXS when he was 14 years old. He has full 
mutation of FMR1 with 185, 440 and 1,100 CGG repeats, 
and without FMR1 mRNA. His mother and his maternal 
grandfather are premutation carriers. He received an ad-
ditional diagnosis of generalized anxiety disorder. He ex-
hibited periods of aggressive outbursts, poor eye contact, 
tactile defensiveness and perseveration in speech. He has 
been prescribed several medications to treat his symptoms 
in the past including methylphenidate, citalopram, minocy-
cline and sertraline. At the age of 22, he was on metformin 
with an increase from 500  mg at dinner to 500  mg bid. 
At present he is on simvastatin 10 mg/day and metformin 
500 mg bid.
Currently, on physical examination, he has typical fea-
tures of FXS. He has hand calluses and minimal arch on his 
feet. He had a normal neurological exam and DTRs were 2+ 
in all four extremities. Summary of the diagnostic findings is 
presented in Table 1.
Baseline (at the age of 19  years, i.e. before he started 
metformin) and follow‐up IQ scores after 1 year of usage of 
metformin (at the age of 23/24 years) are given in Table 2. 
At age 23, he and his caretaker were interviewed with the 
K‐SADS‐PL (a semi‐structured clinical interview). The pa-
tient met DSM‐5 criteria for social phobia and agoraphobia, 
and the clinician noted a decrease in autism spectrum‐related 
symptoms from the previous year.
He continued on metformin and had an excellent response 
to metformin over the subsequent 17  months. He does not 
have loose stools which is the most frequent side effect of 
metformin. Also, he does not have any other side effect of 
metformin. He has experienced significant improvement in 
his communication and behavior. He now enjoys outdoor ac-
tivities. He socializes more and invites friends over. He works 
in a group doing landscaping and seems to be happy with his 
life. He is calmer and he has not had any outbursts over the 
last year. He is less verbally and physically aggressive to other 
children and adults. He talks less excessively and he has less 
repetitive speech. He pays more attention to the instructions. 
He is less distractible. His self‐esteem has also improved con-
siderably. He has new skills since he started on metformin 
including taking the bus independently and cooking meals. 
He wants to earn money for his work and he wants to spend 
it on his own things. The behaviour observations correspond 
to his age of 22–25  years. During this time period he was 
continuously on metformin. However, there were no changes 
in the patient's living conditions, additional therapies, or oc-
cupational status from time point 1 (age of 22 years) to time 
point 2 (age of 25 years).
3.2 | Case 2
This case is a mosaic 30‐year‐old male initially diagnosed 
with FXS when he was 21 months old. His mother and ma-
ternal grandmother are premutation carriers. Furthermore, he 
was diagnosed with anxiety disorder and ASD with a history 
of panic attacks, moodiness, becoming nervous interacting 
with unfamiliar people and shyness. His symptoms included 
hand flapping, poor eye contact, perseveration in speech, 
tactile defensiveness and periods of outbursts. He had early 
intervention from 20 months of age. He has been prescribed 
several medications to treat his symptoms in the past includ-
ing mavoglurant and sertraline. He had been on metformin 
1,000 mg ER once a day for 1 year. His current medications 
include calcium, multivitamins including Vitamin D and B, 
probiotics, magnesium citrate and Coenzyme Q10.
He was delivered at term and by normal delivery. He was 
hypotonic but grew very tall in early age. He was mildly de-
layed in milestones. His early developmental milestones in-
cluded sitting at 6 months, crawling at 7 months, walking not 
until 31 months, and he said single words at 2 years of age, 
and he put together phrases at about 4 years of age. An autism 
assessment at age 22 showed an ADOS (Module 4) score of 
11, which is above the cut‐off for ASDs.
On physical examination, he spoke in short sentences, but 
sometimes mumbled and his eye contact was limited during 
examination. Typical features of FXS were present. He had 
flat, out‐turned and pronated feet. He had a normal neurolog-
ical exam with reflexes 2+ symmetrical in all four extremities 
but he could not tandem walk. Clinical presentation of this 
patient and his lab results are shown in Table 1.
He started on metformin when he was 29 years old, and 
baseline (at the age of 26 years; i.e. before he started met-
formin) and follow‐up IQ scores after 1 year of metformin 
usage (at the age of 30 years) are given in Table 2. Usually, 
there is a decline in cognitive skills in FXS with age, which 
was not the case here.
Parents reported that metformin has had a significant ef-
fect on his language. He has been more verbal since starting 
metformin; he shares his thoughts more often, and he asks 
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more questions. The expressive language improvements 
occurred right away after metformin was titrated to the full 
dose, but he still has mild articulation difficulties. Since the 
start of metformin treatment, he has started to do familiar 
tasks/chores more often on his own initiative. He does not 
have loose stools, and no other side effects were reported. 
He works 4 days a week at a grocery store, but there were 
no changes in the patient's living conditions and additional 
therapies from time point 1 to time point 2. He continues to 
be physically active, going to the gym with his parents. He 
enjoys walking. The time period of behavioral observation 
corresponds to metformin usage: the baseline for the behav-
ioral evaluation was when he was 29 years old, the follow‐up 
when he was 30 years old.
4 |  DISCUSSION
This is the first paper which describes individuals with FXS 
who have shown an improvement in IQ scores after treatment 
with metformin.
On baseline, scores of both patients on overall intellectual 
ability, nonverbal ability, and verbal ability, were lower rel-
ative to the normative sample. After one year of metformin, 
test results reveal an increase in Full Scale IQ (from 53 to 57 
and from 47 to 51), Nonverbal IQ (from 50 to 52 and from 58 
to 68) and Verbal IQ (from 61 to 66 and from 50 to 58) for 
both patients (See Table 2). Moreover, improvements in factor 
index scales were seen in measures of visuospatial processing 
and knowledge of spatial relations, working memory, as well 
as numeracy skills and quantitative reasoning (see Table 2). 
These changes were driven by better performances in both in 
nonverbal and verbal tasks (see Table 2), with the latter sug-
gesting subtle, qualitative improvements in their capacity to 
use language more effectively to comprehend instructions, 
recall information, and provide appropriate responses. While 
an IQ increase of 1–5 points is not statistically significant and 
could be within normal limits, since a 10‐point increase (1 
standard deviation) is needed to be considered significant, the 
fact that both adults remained stable in most areas measured 
on the Stanford–Binet and did not show a decline in their cog-
nitive functioning, is noteworthy. These results suggest that 
regression or deterioration in abilities in most domains on 
the cognitive measure did not occur. In fact, gains were also 
seen on item level analysis in terms of their number of cor-
rect responses some tasks. More importantly, these contrast 
with known IQ trajectories in FXS among young adult males, 
including those with comorbid ASD, where an early plateau 
in mental age eventually leads to the widening gap between 
expected capacities and cognitive performance over time.
Previous studies documented IQ score declines with 
aging in males and females with FXS (Schneider, Ligsay, & 
Hagerman, 2013). Lachiewicz, Gullion, Spiridigliozzi, and 
Aylsworth (1987) first published data about IQ declines in 
individuals with FXS during childhood. Borghgraef et al. 
(2002) described IQ changes in ten individuals with FXS 
aged from 33 to 65 years. They concluded that the declines 
were most notably in the verbal communication skills and 
that the use of language declined in these individuals over 
time (Borghgraef et al., 2002). IQ decline was also found in 
39 males with FXS aged from 4 to 26 years (Wiegers, Curfs, 
Vermeer, & Fryns, 1993). Hagerman et al. (1989) published 
that individuals with FXS with the highest IQs had the great-
est cognitive decline. Also, similar results were published in 
1996 by Wright‐Talamante et al. (1996).
Here we present two adult individuals with FXS who 
experienced benefits for language and cognition from met-
formin. These two patients have been treated clinically with 
metformin, as a targeted treatment in FXS. In addition to the 
general improvement in cognitive skills, both individuals 
have notable improvements in communication, social activ-
ities and behavior. They also demonstrated improved eating 
habits. Metformin has seemed to slightly decrease anxiety in 
these individuals with FXS.
The use of metformin in the Drosophila FXS model 
rescued the circadian rhythm deficits and memory deficits 
(Monyak et al., 2017). Preclinical studies performed in FXS 
KO mouse demonstrated that metformin could improve FXS 
phenotypes, including grooming, social novelty, electro-
physiology in eCA1 of the hippocampus and dendritic spine 
morphology. Pathogenically overactive signaling pathways in 
FXS in the central nervous system, mTOR and PI3K, could 
be normalized by metformin (Gantois et al., 2017). This 
medication inhibits MMP9 production which is elevated in 
FXS (Dziembowska et al., 2013; Hoeffer et al., 2012; Muzar, 
Lozano, Kolevzon, & Hagerman, 2016).
T A B L E  2  The results of Stanford–Binet IQ testing
Case
Time of 
testing
Nonverbal 
IQ
Verbal 
IQ
Full scale 
IQ
Fluid 
reasoning Knowledge
Quantitative 
reasoning
Verbal‐spatial 
processing
Working 
memory
Case 1 Baseline 50 61 53 65 72 53 59 51
Follow‐up 52 66 57 65 66 56 71 60
Case 2 Baseline 47 58 50 68 66 50 48 57
Follow‐up 51 68 58 68 72 61 56 63
Note: Baseline‐IQ testing before introduction of metformin; Follow‐up—IQ testing after one‐year usage of metformin.
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Based on the potential regulation of intracellular signaling 
pathways, the results of preclinical studies and our previous 
and current clinical studies, metformin appears to be a good 
targeted treatment for some of the disrupted intracellular 
functions in neurons of individuals with FXS. Thus, met-
formin may be a candidate drug for treatment of several types 
of symptoms in individuals with FXS. Preventing the cogni-
tive decline in FXS can increase the quality of life and prog-
nosis for semi‐independent living skills (Gorelick, 2018). 
However, the limitation of this study could include possible 
placebo effect. Specifically, parent reports about the behavior 
changes in both individuals were not quantified with an adap-
tive behavior measurement, and other standardized scales.
The first randomized, double‐blind controlled clinical 
trial of safety, tolerability and efficacy of metformin in the 
treatment of language deficits, behavior problems, and obe-
sity/excessive appetite in individuals with FXS is currently 
taking place for individuals ages 6–25  years (NCT num-
ber: NCT03479476). The dose of metformin is titrated in a 
weight‐dependent manner over the four weeks. The level of 
MMP9 as a biomarker is assessed. The first results will be 
expected in 2021 and the study will access the efficacy of 
metformin for behavior and cognition in patients with FXS.
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